Clarivate PLC (CLVT) · Nov 3, 2026 · Earnings

Clarivate earnings beat as recurring growth offsets portfolio shrinkage

Beat — Adjusted EPS $0.21 vs ~$0.18 consensus

Clarivate’s Q3 earnings beat expectations, with improving recurring growth and debt reduction offsetting weaker cash flow and portfolio-driven revenue declines.

Clarivate is now a focused two-segment data and software company built around Academia & Government and Intellectual Property, using subscription products and AI tools to replace divested or declining transactional businesses. The Life Sciences & Healthcare sale was already known before this release, so the strategic reset itself is partly priced into the event.

The quarter cleared the earnings bar. Total revenue of $567.9 million was roughly in line with the published consensus of about $566.8 million, while adjusted diluted EPS of $0.21 exceeded the roughly $0.18 expectation. The filing states, “Adjusted net income, including LS&H, was $136.0million, or $0.21per diluted share, compared to $119.3million, or $0.18per diluted share.”

MetricQ3 2026Q3 2025Consensus
Revenue, including discontinued operations (Selected Financial Information)$567.9M$623.1M$566.8M
Adjusted diluted EPS (Selected Financial Information)$0.21$0.18$0.18
Adjusted EBITDA, continuing operations (Selected Financial Information)$218.2M$222.2M
Free cash flow (Selected Financial Information)$110.2M$115.5M

The underlying business is improving, but only gradually. Continuing-operations organic revenue rose 0.4%, organic recurring revenue rose 1.3%, and organic ACV rose 1.8%; that is credible progress toward a subscription-led model, but not yet a high-growth recovery. The tradeoff is visible in transactional revenue, which fell 12.4% organically as Clarivate winds down lower-quality products and migrates customers toward subscriptions. The filing says, “Recurring revenues, which consist of subscription and re-occurring revenues, increased 1.3% organically, or $5.7million.”

Margins show better execution, while cash conversion remains the weak spot. Continuing-operations adjusted EBITDA margin expanded to 45.3% from 41.9%, helped by cost control and portfolio pruning, but adjusted EBITDA itself declined modestly and nine-month free cash flow fell 15.6% year over year. The filing reports, “Free cash flow including discontinued operations for the first nine months of 2026 was $233.1million compared to $276.1million in the prior year period.”

The guidance update is mostly a portfolio recast, not a clean operating upgrade. Full-year revenue and EBITDA guidance now exclude LS&H for the fourth quarter, while the nine-month contribution remains in full-year EPS and free cash flow. Relative to the prior outlook, the implied continuing-business ranges are broadly maintained, but free cash flow is lower because of transaction timing, working-capital effects, and one-time costs. The divestiture does improve financial flexibility: Clarivate received $488.4 million of net cash proceeds and plans to apply proceeds and fourth-quarter cash flow toward another roughly $575 million to $600 million of debt repayment.

Bottom line: This was a genuine earnings beat with improving recurring growth and margins, but the business is still replacing lost revenue rather than accelerating meaningfully. The event modestly strengthens the turnaround story; it does not rewrite it.

What to watch next

IPOne early-adopter launch in November 2026

Original filing on SEC EDGAR

Clarivate earnings beat as recurring growth offsets portfolio shrinkage | CLVT Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.